DE814775T1 - Methode und kit zur verhütung erektiler dysfunktion - Google Patents
Methode und kit zur verhütung erektiler dysfunktionInfo
- Publication number
- DE814775T1 DE814775T1 DE0814775T DE96910378T DE814775T1 DE 814775 T1 DE814775 T1 DE 814775T1 DE 0814775 T DE0814775 T DE 0814775T DE 96910378 T DE96910378 T DE 96910378T DE 814775 T1 DE814775 T1 DE 814775T1
- Authority
- DE
- Germany
- Prior art keywords
- agent
- vasoactive
- use according
- kit
- vasoactive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims 4
- 201000001881 impotence Diseases 0.000 title claims 4
- 239000002550 vasoactive agent Substances 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 9
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 6
- 210000003708 urethra Anatomy 0.000 claims 5
- 239000002160 alpha blocker Substances 0.000 claims 4
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 4
- 239000002220 antihypertensive agent Substances 0.000 claims 4
- 229940030600 antihypertensive agent Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003961 penetration enhancing agent Substances 0.000 claims 4
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 4
- 229960001289 prazosin Drugs 0.000 claims 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 3
- 229940127450 Opioid Agonists Drugs 0.000 claims 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 3
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 3
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims 3
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims 3
- 239000011575 calcium Substances 0.000 claims 3
- 229910052791 calcium Inorganic materials 0.000 claims 3
- 229960001076 chlorpromazine Drugs 0.000 claims 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 3
- 239000002270 dispersing agent Substances 0.000 claims 3
- 229940052760 dopamine agonists Drugs 0.000 claims 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 229960003878 haloperidol Drugs 0.000 claims 3
- 150000002823 nitrates Chemical class 0.000 claims 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 3
- 150000003180 prostaglandins Chemical class 0.000 claims 3
- 230000002227 vasoactive effect Effects 0.000 claims 3
- 229960000317 yohimbine Drugs 0.000 claims 3
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims 3
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 2
- 229960003133 ergot alkaloid Drugs 0.000 claims 2
- 210000003899 penis Anatomy 0.000 claims 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000331 vasculogenic impotence Diseases 0.000 claims 1
- 230000000982 vasogenic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/41—Devices for promoting penis erection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/16—Male reproductive, genital organs
- A61M2210/167—Penis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nursing (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (23)
1. Verwendung eines vasoaktiven Agens bei der Herstellung eines Medikamentes
zur Vermeidung von Erektionsstörungen bei einem männlichen Individuum durch Verabreichung dieses Agens an das Individuum nach Maßgabe einer Dosierungsregel,
um einen regulären, verstärkten Blutstrom zum Penis zu bewirken.
2. Verwendung nach Anspruch 1, wobei das vasoaktive Agens transurethral
verabreicht wird
3. Verwendung nach Anspruch 2, bei der die Dosierungsregel die Verabreichung
einer vorbestimmten Dosis des vasoaktiven Agens zwei- bis sechsmal in einer 24-Stunden-Periode
vorschreibt.
4. Verwendung nach Anspruch 1, bei der die Erektionsstörung eine vasculogene
Impotenz ist.
5. Verwendung nach Anspruch 2, bei der die Verabreichung der Droge in der
Weise ausgeführt wird, daß das vasoaktive Agens mit der männlichen Urethra an einer
Stelle zwischen dem Nahbereich der Fossa Navicularis und dem Fernbereich von der
pendelnden Urethra in Kontakt gebracht wird, so daß die Droge in den Blutstrom des
Individuums durch die Wand der Urethra eintritt.
6. Verwendung nach Anspruch 5, bei der das Agens in einem Dispergierungsmittel
verabreicht wird, welches den Agens in der Urethra in der genannten Tiefe in einem
Gewichtsverhältnis von Dispergierungsmittel zu Agens von etwa 1 : 1 bis 50 : 1 freigibt, wobei die Menge der Dosis das Dosis-Rückhaltevermögen der Urethra nicht
übersteigt.
7. Verwendung nach Anspruch 6, bei der die Menge von Agens und Dispergierungsmittel
die transurethral verabreicht wird, etwa 50 mg beträgt.
8. Verwendung nach Anspruch 2, bei der ein transurethraler Permeationsverstärker
gemeinsam mit dem vasoaktiven Agens verabreicht wird.
9. Verwendung nach Anspruch 8, bei der der transurethrale Permeationsverstärker
und das vasoaktive Agens gleichzeitig verabreicht werden.
10. Verwendung nach Anspruch 9, bei der der transurethrale Permeationsverstärker
und das vasoaktive Agens in einer einzigen pharmazeutischen Zusammensetzung verabreicht werden.
11. Verwendung nach Anspruch 8, bei der der transurethrale Permationsverstärker
und das vasoaktive Agens nacheinander verabreicht werden.
12. Verwendung nach Anspruch 1, bei der das vasoaktive Agens aus der Gruppe
ausgewählt wird, die aus anti hypersensitiven V\firkstoffen, Nitraten, lang- und kurzzeitwirkenden
a-Blockern, Kalziumblockern, Ergot-AJkaloiden, Chlorpromazin, Haloperidol,
Yohimbin, natürlichen und synthetischen vasoaktiven Prostaglandin und ihren
Analogika, vasoaktiven intestinalen Peptiden, Dopamin Agonistika, Opioden Agonistika
und Kombinationen davon besteht.
13. Verwendung nach Anspruch 12, bei der das vasoaktive Agens aus der Gruppe
ausgewählt ist, die aus antohypersensitiven Agens, Nitraten, lang- und kurzzeitwirkenden
a-Blockern, Kalziumblockern, Ergot-Alkaloiden, Chlorpromazin, Haloperidol,
Yohimbin, natürlichen und synthetischen vasoaktiven Prostaglandin und ihren
Analogika, vasoaktiven intestinalen Peptiden, Dopamin Agonistika, Opioden Agonistika
und Kombinationen davon besteht.
14. Verwehdung nach Anspruch 13, bei der das vasoaktive Agens ein antihypertensitiver
Agens ist.
15. Verwendung nach Anspruch 14, bei der antihypertensitive Agens Prazosin ist.
16. Verwendung nach Anspruch 13, bei der das vasoaktive Agens Prostaglandin E1
ist.
17. Verwendung nach Anspruch 13, bei der Prazosin und Prostaglandin E, gleichzeitig
verabreicht werden.t
18. Ausrüstung zur Vermeidung vaskulogener Erektionsstörungen bei einem
männlichen Individuum, welche Ausrüstung aufweist: ein vasoaktives Agens, das zur
Verstärkung des Blutstromes zum Penis wirksam ist; eine Drogenverabreichungshilfe
zur Verabreichung des vasoaktiven Agens, einen Behälter zur Unterbringung des Agens und der Drogenverabreichungshilfe und geschriebene Instruktionen über die
Verwendung des Agens und der Drogenverabreichungshilfe.
19. Ausrüstung nach Anspruch 18, bei der das vasoaktive Agens aus der Gruppe
ausgewählt wird, die aus antihypersensitiven Wirkstoffen, Nitraten, lang- und kurzzeitwirkenden
a-Blockern, Kalziumblockern, Ergot-Alkaloiden, Chlorpromazin, Haloperidol,
Yohimbin, natürlichen und synthetischen vasoaktiven Prostaglandin und ihren
Analogika, vasoaktiven intestinalen Peptiden, Dopamin Agonistika, Opioden Agonistika
und Kombinationen davon besteht.
20. Ausrüstung nach Anspruch 19, bei der das vasoakive Agens ein antihypertensitives
Agens ist.
21. Ausrüstung nach Anspruch 20, bei der das antihypertensitive Agens Prazosin
ist.
22. Ausrüstung nach Anspruch 19, bei der das vasoaktive Agens Prostaglandin E1
ist
23. Ausrüstung nach Anspruch 19, die Prazosin und Prostaglandin E1 enthält.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40333395A | 1995-03-14 | 1995-03-14 | |
| PCT/US1996/003086 WO1996028142A1 (en) | 1995-03-14 | 1996-03-07 | Method and kit for preventing erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE814775T1 true DE814775T1 (de) | 1998-06-25 |
Family
ID=23595398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0814775T Pending DE814775T1 (de) | 1995-03-14 | 1996-03-07 | Methode und kit zur verhütung erektiler dysfunktion |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5820587A (de) |
| EP (1) | EP0814775A1 (de) |
| JP (1) | JPH10505611A (de) |
| KR (1) | KR19980703052A (de) |
| AU (1) | AU5358896A (de) |
| BR (1) | BR9607365A (de) |
| CA (1) | CA2215307A1 (de) |
| CZ (1) | CZ278497A3 (de) |
| DE (1) | DE814775T1 (de) |
| ES (1) | ES2110380T1 (de) |
| HU (1) | HUP9801324A3 (de) |
| NO (1) | NO974062L (de) |
| NZ (1) | NZ305560A (de) |
| PL (1) | PL322268A1 (de) |
| SK (1) | SK124397A3 (de) |
| TR (1) | TR199700930T2 (de) |
| WO (1) | WO1996028142A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
| JP2001509480A (ja) | 1997-07-09 | 2001-07-24 | アンドロソリューションズ，インク． | 男性勃起機能不全を治療するための改良された方法及び組成物 |
| US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
| US5947901A (en) * | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
| US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
| US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
| US6228864B1 (en) | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
| ES2155740B1 (es) * | 1998-03-31 | 2001-12-01 | Vita Invest Sa | Dispositivo intrauretral para el tratamiento de la disfuncion erectil. |
| US6056966A (en) * | 1998-05-18 | 2000-05-02 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for treating impotence |
| GR1003199B (el) | 1998-08-14 | 1999-09-01 | Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες | |
| CA2340206A1 (en) | 1998-08-26 | 2000-03-09 | Queen's University At Kingston | Use of anti-pressor agents for vascular remodeling in genital dysfunction |
| KR100350179B1 (ko) * | 1998-09-23 | 2002-08-27 | 구주제약주식회사 | Ｓｅｄｄｓ로 제제화한 발기부전치료용 주입액제 |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| FR2789586A1 (fr) * | 1999-02-16 | 2000-08-18 | Synthelabo | Composition pharmaceutique pour administration transmucosale balanique d'alfuzosine |
| AU3713600A (en) * | 1999-03-01 | 2000-09-21 | Nitromed, Inc. | Nitrosated and nitrosylated prostaglandins, compositions and metods of use |
| IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| US6693135B2 (en) | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US6323241B1 (en) | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| KR20010076961A (ko) * | 2000-01-29 | 2001-08-17 | 김제종 | 성기능장애 예방 및 치료용 약제 |
| GB0130704D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | New use |
| SI1750766T1 (sl) | 2004-05-11 | 2013-11-29 | Emotional Brain B.V. | Farmacevtske formulacije in njihove uporabe pri zdravljenju spolne disfunkcije pri Ĺľenskah |
| EP1790343A1 (de) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau |
| EP1925307A1 (de) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| CA2737461A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
| EP3284494A1 (de) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Tragbares infusionspumpensystem |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| BR102019016950A2 (pt) * | 2019-08-15 | 2021-02-23 | Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu | forma de dosagem intrauretral de medicamento; e dispositivo |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2097520A5 (de) * | 1970-07-09 | 1972-03-03 | Morel Paul | |
| US3797493A (en) * | 1970-11-20 | 1974-03-19 | E Saudek | Single use container, especially for pharmaceutical material |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| CA1135827A (en) * | 1978-12-04 | 1982-11-16 | Rainer Fehr | Determination of flow velocities by measuring phase difference between the doppler signals |
| US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| JPS5836528A (ja) * | 1981-08-28 | 1983-03-03 | 株式会社東芝 | 超音波パルスドツプラ血流測定装置 |
| US4612937A (en) * | 1983-11-10 | 1986-09-23 | Siemens Medical Laboratories, Inc. | Ultrasound diagnostic apparatus |
| US4585005A (en) * | 1984-04-06 | 1986-04-29 | Regents Of University Of California | Method and pacemaker for stimulating penile erection |
| US4828544A (en) * | 1984-09-05 | 1989-05-09 | Quotidian No. 100 Pty Limited | Control of blood flow |
| US5219885A (en) * | 1987-02-16 | 1993-06-15 | Froelich Juergen | Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration |
| US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US4889238A (en) * | 1989-04-03 | 1989-12-26 | The Procter & Gamble Company | Medicament package for increasing compliance with complex therapeutic regimens |
| US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| EP0526566B1 (de) * | 1990-04-25 | 1998-11-25 | Vivus, Inc. | Behandlung von erektionversagen |
| EP0459666B1 (de) * | 1990-05-31 | 1994-11-09 | Pfizer Inc. | Arzneimittel gegen Impotenz |
| US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
| US5148920A (en) * | 1991-03-18 | 1992-09-22 | Zimmer, Inc. | Package and package insert |
| DE4117249C2 (de) * | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| AU2300092A (en) * | 1991-07-03 | 1993-02-11 | Nathan E. Scott | Prostaglandin e2 treatment of impotence |
| US5482039A (en) * | 1994-03-25 | 1996-01-09 | Vivus, Inc. | Process for diagnosing erectile dysfunction, and related methods of treatment |
-
1996
- 1996-03-07 SK SK1243-97A patent/SK124397A3/sk unknown
- 1996-03-07 PL PL96322268A patent/PL322268A1/xx unknown
- 1996-03-07 CZ CZ972784A patent/CZ278497A3/cs unknown
- 1996-03-07 AU AU53588/96A patent/AU5358896A/en not_active Abandoned
- 1996-03-07 EP EP96910378A patent/EP0814775A1/de not_active Withdrawn
- 1996-03-07 TR TR97/00930T patent/TR199700930T2/xx unknown
- 1996-03-07 JP JP8527704A patent/JPH10505611A/ja active Pending
- 1996-03-07 ES ES96910378T patent/ES2110380T1/es active Pending
- 1996-03-07 KR KR1019970706461A patent/KR19980703052A/ko not_active Application Discontinuation
- 1996-03-07 DE DE0814775T patent/DE814775T1/de active Pending
- 1996-03-07 WO PCT/US1996/003086 patent/WO1996028142A1/en not_active Application Discontinuation
- 1996-03-07 BR BR9607365A patent/BR9607365A/pt not_active Application Discontinuation
- 1996-03-07 HU HU9801324A patent/HUP9801324A3/hu unknown
- 1996-03-07 NZ NZ305560A patent/NZ305560A/en unknown
- 1996-03-07 CA CA002215307A patent/CA2215307A1/en not_active Abandoned
-
1997
- 1997-03-17 US US08/819,620 patent/US5820587A/en not_active Expired - Lifetime
- 1997-09-04 NO NO974062A patent/NO974062L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO974062D0 (no) | 1997-09-04 |
| PL322268A1 (en) | 1998-01-19 |
| NZ305560A (en) | 1998-11-25 |
| US5820587A (en) | 1998-10-13 |
| NO974062L (no) | 1997-09-15 |
| CA2215307A1 (en) | 1996-09-19 |
| ES2110380T1 (es) | 1998-02-16 |
| MX9707038A (es) | 1997-11-29 |
| EP0814775A1 (de) | 1998-01-07 |
| JPH10505611A (ja) | 1998-06-02 |
| CZ278497A3 (cs) | 1998-04-15 |
| HUP9801324A2 (hu) | 1998-09-28 |
| KR19980703052A (ko) | 1998-09-05 |
| HUP9801324A3 (en) | 1999-03-29 |
| AU5358896A (en) | 1996-10-02 |
| TR199700930T2 (xx) | 1998-07-21 |
| SK124397A3 (en) | 1998-12-02 |
| BR9607365A (pt) | 1997-12-30 |
| WO1996028142A1 (en) | 1996-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE814775T1 (de) | Methode und kit zur verhütung erektiler dysfunktion | |
| Clarke et al. | Medetomidine, a new sedative‐analgesic for use in the dog and its reversal with atipamezole | |
| Resnick et al. | Studies of EN-1639A (naltrexone): a new narcotic antagonist | |
| DE69017596T2 (de) | Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung. | |
| US6376550B1 (en) | Pharmaceutical compositions containing tramadol for migraine | |
| US6121276A (en) | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction | |
| EP0978282A2 (de) | Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz | |
| KAUR et al. | Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double‐blind study | |
| Nimmo et al. | Gastric emptying following hysterectomy with extradural analgesia | |
| US5187177A (en) | Method and a pharmaceutical preparation for treating pain | |
| EP0540623A1 (de) | Oral anzuwendende osmotische vorrichtung zur abgabe von nicotin. | |
| US6566368B2 (en) | Apomorphine-containing dosage form for ameliorating male erectile dysfunction | |
| JPH02188525A (ja) | 間質性膀胱炎に対する治療用医薬組成物 | |
| Burks et al. | Responses of isolated dog small intestine to analgesic agents | |
| DE3343934A1 (de) | M-chlor-(alpha)-tert.-butylaminopropiophenon und seine verwendung zur senkung des cholesterolspiegels | |
| KR20010021505A (ko) | 발기 부전을 치료하기 위한 요힘빈 및 아르기닌 함유 약제 | |
| NO20001828L (no) | Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus | |
| KR890014109A (ko) | 의약제 | |
| US4639455A (en) | Means of aiding in the prevention of sudden infant death syndrome | |
| Staquet | Analgesic effect of ciramadol in patients with chronic pain | |
| Whitwam | A clinical comparison of the incidence and duration of apnoea following methohexitone and thiopentone | |
| JPH0569093B2 (de) | ||
| Wiseman et al. | Development of a sustained‐release aspirin tablet | |
| Morrison et al. | Studies of drugs given before anaesthesia XVIII: The synthetic opiates | |
| JPH0232020A (ja) | モルフィン鎮痛治療における耐性発現の抑制方法および薬剤 |